The Role of Tissue Inhibitors of Metalloproteinases in Tumorigenesis and Metastasis

REFERENCES

• Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 2000; 1477: 267–283
   PubMed Web of Science ®Google Scholar
• Montagnani C, Le Roux F, Berthe F, Escoubas J M. Cg-TIMP, an inducible tissue inhibitor of metalloproteinase from the Pacific oyster Crassostrea gigas with a potential role in wound healing and defense mechanisms(1). FEBS Lett 2001; 500: 64–70
   Google Scholar
• Carmichael D F, Sommer A, Thompson R C, Anderson D C, Smith C G, Welgus H G, Stricklin G P. Primary structure and cDNA cloning of human fibroblast collagenase inhibitor. Proc Natl Acad Sci U S A 1986; 83: 2407–2411
   PubMed Web of Science ®Google Scholar
• Docherty A J, Lyons A, Smith B J, Wright E M, Stephens P E, Harris T J, Murphy G, Reynolds J J. Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity. Nature 1985; 318: 66–69
   PubMed Web of Science ®Google Scholar
• Stetler-Stevenson W G, Brown P D, Onisto M, Levy A T, Liotta L A. Tissue inhibitor of metalloproteinases-2 (TIMP2) mRNA expression in tumor cell lines and human tumor tissues. J Biol Chem 1990; 265: 13933–13938
   PubMed Web of Science ®Google Scholar
• Hammani K, Henriet P, Silbiger S M, DeClerck Y A. Cloning and partial structure of the gene encoding human tissue inhibitor of metalloproteinases-3. Gene 1996; 170: 287–288
   Google Scholar
• Greene J, Wang M, Liu Y E, Raymond L A, Rosen C, Shi Y E. Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. J Biol Chem 1996; 271: 30375–30380
   PubMed Web of Science ®Google Scholar
• Leco K J, Hayden L J, Sharma R R, Rocheleau H, Greenberg A H, Edwards D R. Differential regulation of TIMP1 and TIMP2 mRNA expression in normal and Ha-ras-transformed murine fibroblasts. Gene 1992; 117: 209–217
   PubMed Web of Science ®Google Scholar
• Leco K J, Khokha R, Pavloff N, Hawkes S P, Edwards D R. Tissue inhibitor of metalloproteinases-3 (TIMP3) is an extracellular matrix-associated protein with a distinctive pattern of expression in mouse cells and tissues. J Biol Chem 1994; 269: 9352–9360
   PubMed Web of Science ®Google Scholar
• Leco K J, Apte S S, Taniguchi G T, Hawkes S P, Khokha R, Schultz G A, Edwards D R. Murine tissue inhibitor of metalloproteinases-4 (Timp4): cDNA isolation and expression in adult mouse tissues. FEBS Lett 1997; 401: 213–217
   PubMed Web of Science ®Google Scholar
• Murphy G, Reynolds J J, Hembry R M. Metalloproteinases and cancer invasion and metastasis. Int J Cancer 1989; 44: 757–760
   Google Scholar
• Nagase H, Woessner J F, Jr. Matrix metalloproteinases. J Biol Chem 1999; 274: 21491–21494
   PubMed Web of Science ®Google Scholar
• Fata J E, Ho A T, Leco K J, Moorehead R A, Khokha R. Cellular turnover and extracellular matrix remodeling in female reproductive tissues: functions of metalloproteinases and their inhibitors. Cell Mol Life Sci 2000; 57: 77–95
   Google Scholar
• Hojilla C V, Mohammed F F, Khokha R. Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development. Br J Cancer 2003; 89: 1817–1821
   PubMed Web of Science ®Google Scholar
• Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002; 2: 161–174
   PubMed Web of Science ®Google Scholar
• Folgueras A R, Pendas A M, Sanchez L M, Lopez-Otin C. Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int J Dev Biol 2004; 48: 411–424
   PubMed Web of Science ®Google Scholar
• Hanahan D. Dissecting multistep tumorigenesis in transgenic mice. Annu Rev Genet 1988; 22: 479–519
   PubMed Web of Science ®Google Scholar
• Fearon E R, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759–767
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg R A. The hallmarks of cancer. Cell 2000; 100: 57–70
   PubMed Web of Science ®Google Scholar
• Hahn W C, Weinberg R A. Rules for making human tumor cells. N Engl J Med 2002; 347: 1593–1603
   PubMed Web of Science ®Google Scholar
• Valverde J R, Alonso J, Palacios I, Pestana A. RB1 gene mutation up-date, a meta-analysis based on 932 reported mutations available in a searchable database. BMC Genet 2005; 6: 53
   PubMed Web of Science ®Google Scholar
• Helt A M, Galloway D A. Mechanisms by which DNA tumor virus oncoproteins target the Rb family of pocket proteins. Carcinogenesis 2003; 24: 159–169
   PubMed Web of Science ®Google Scholar
• Sansal I, Sellers W R. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004; 22: 2954–2963
   PubMed Web of Science ®Google Scholar
• Chow L M, Baker S J. PTEN function in normal and neoplastic growth. Cancer Lett 2006; 241: 184–196
   PubMed Web of Science ®Google Scholar
• Behrens J. The role of the Wnt signalling pathway in colorectal tumorigenesis. Biochem Soc Trans 2005; 33: 672–675
   PubMed Web of Science ®Google Scholar
• Ellis H M, Horvitz H R. Genetic control of programmed cell death in the nematode C. elegans. Cell 1986; 44: 817–829
   PubMed Web of Science ®Google Scholar
• Okada H, Mak T W. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer 2004; 4: 592–603
   PubMed Web of Science ®Google Scholar
• Ghobrial I M, Witzig T E, Adjei A A. Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin 2005; 55: 178–194
   PubMed Web of Science ®Google Scholar
• Bristow R G, Benchimol S, Hill R P. The p53 gene as a modifier of intrinsic radiosensitivity: implications for radiotherapy. Radiother Oncol 1996; 40: 197–223
   PubMed Web of Science ®Google Scholar
• Weinmann M, Jendrossek V, Handrick R, Guner D, Goecke B, Belka C. Molecular ordering of hypoxia-induced apoptosis: critical involvement of the mitochondrial death pathway in a FADD/caspase-8 independent manner. Oncogene 2004; 23: 3757–3769
   PubMed Web of Science ®Google Scholar
• Hammond E M, Giaccia A J. The role of p53 in hypoxia-induced apoptosis. Biochem Biophys Res Commun 2005; 331: 718–725
   PubMed Web of Science ®Google Scholar
• Fridman J S, Lowe S W. Control of apoptosis by p53. Oncogene 2003; 22: 9030–9040
   PubMed Web of Science ®Google Scholar
• Heiser D, Labi V, Erlacher M, Villunger A. The Bcl-2 protein family and its role in the development of neoplastic disease. Exp Gerontol 2004; 39: 1125–1135
   PubMed Web of Science ®Google Scholar
• Jerome L, Shiry L, Leyland-Jones B. Deregulation of the IGF axis in cancer: epidemiological evidence and potential therapeutic interventions. Endocr Relat Cancer 2003; 10: 561–578
   PubMedGoogle Scholar
• Kelland L R. Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics–current status and future prospects. Eur J Cancer 2005; 41: 971–979
   PubMed Web of Science ®Google Scholar
• Reddel R R. Alternative lengthening of telomeres, telomerase, and cancer. Cancer Lett 2003; 194: 155–162
   PubMed Web of Science ®Google Scholar
• Dimri G P. What has senescence got to do with cancer?. Cancer Cell 2005; 7: 505–512
   PubMed Web of Science ®Google Scholar
• Rak J, Yu J L, Klement G, Kerbel R S. Oncogenes and angiogenesis: signaling three-dimensional tumor growth. J Investig Dermatol Symp Proc 2000; 5: 24–33
   PubMed Web of Science ®Google Scholar
• Bergers G, Benjamin L E. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3: 401–410
   PubMed Web of Science ®Google Scholar
• Belotti D, Paganoni P, Manenti L, Garofalo A, Marchini S, Taraboletti G, Giavazzi R. Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res 2003; 63: 5224–5229
   PubMed Web of Science ®Google Scholar
• Liotta L A, Kohn E C. The microenvironment of the tumour-host interface. Nature 2001; 411: 375–379
   PubMed Web of Science ®Google Scholar
• Peters J, Loud J, Dimond E, Jenkins J. Cancer genetics fundamentals. Cancer Nurs 2001; 24: 446–461, quiz 462
   Google Scholar
• Guo Y H, Gao W, Li Q, Li P F, Yao P Y, Chen K. Tissue inhibitor of metalloproteinases-4 suppresses vascular smooth muscle cell migration and induces cell apoptosis. Life Sci 2004; 75: 2483–2493
   PubMed Web of Science ®Google Scholar
• Chang C, Werb Z. The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol 2001; 11: S37–S43
   PubMed Web of Science ®Google Scholar
• Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889; 1: 571–573
   Google Scholar
• Puente X S, Sanchez L M, Overall C M, Lopez-Otin C. Human and mouse proteases: a comparative genomic approach. Nat Rev Genet 2003; 4: 544–558
   PubMed Web of Science ®Google Scholar
• Lynch C C, Matrisian L M. Matrix metalloproteinases in tumor-host cell communication. Differentiation 2002; 70: 561–573
   PubMed Web of Science ®Google Scholar
• Yoon S O, Park S J, Yun C H, Chung A S. Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. J Biochem Mol Biol 2003; 36: 128–137
   PubMedGoogle Scholar
• Hoekstra R, Eskens F A, Verweij J. Matrix metalloproteinase inhibitors: current developments and future perspectives. Oncologist 2001; 6: 415–427
   PubMed Web of Science ®Google Scholar
• Stamenkovic I. Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol 2000; 10: 415–433
   PubMed Web of Science ®Google Scholar
• Denhardt D T, Feng B, Edwards D R, Cocuzzi E T, Malyankar U M. Tissue inhibitor of metalloproteinases (TIMP, aka EPA): structure, control of expression and biological functions. Pharmacol Ther 1993; 59: 329–341
   PubMed Web of Science ®Google Scholar
• He C S, Wilhelm S M, Pentland A P, Marmer B L, Grant G A, Eisen A Z, Goldberg G I. Tissue cooperation in a proteolytic cascade activating human interstitial collagenase. Proc Natl Acad Sci USA 1989; 86: 2632–2636
   PubMed Web of Science ®Google Scholar
• Saari H, Suomalainen K, Lindy O, Konttinen Y T, Sorsa T. Activation of latent human neutrophil collagenase by reactive oxygen species and serine proteases. Biochem Biophys Res Commun 1990; 171: 979–987
   PubMed Web of Science ®Google Scholar
• Matrisian L M. The matrix-degrading metalloproteinases. Bioessays 1992; 14: 455–463
   PubMed Web of Science ®Google Scholar
• Siwik D A, Pagano P J, Colucci W S. Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts. Am J Physiol Cell Physiol 2001; 280: C53–C60
   PubMed Web of Science ®Google Scholar
• Wang Z, Juttermann R, Soloway P D. TIMP2 is required for efficient activation of proMMP-2 in vivo. J Biol Chem 2000; 275: 26411–26415
   PubMed Web of Science ®Google Scholar
• English J L, Kassiri Z, Koskivirta I, Atkinson S J, Di Grappa M, Soloway P D, Nagase H, Vuorio E, Murphy G, Khokha R. Individual Timp deficiencies differentially impact pro-MMP-2 activation. J Biol Chem 2006; 281: 10337–10346
   PubMed Web of Science ®Google Scholar
• Sternlicht M D, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001; 17: 463–516
   PubMed Web of Science ®Google Scholar
• Stamenkovic I. Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol 2003; 200: 448–464
   PubMed Web of Science ®Google Scholar
• Rhee J S, Coussens L M. RECKing MMP function: implications for cancer development. Trends Cell Biol 2002; 12: 209–211
   PubMed Web of Science ®Google Scholar
• Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003; 92: 827–839
   PubMed Web of Science ®Google Scholar
• Forget M A, Desrosiers R R, Beliveau R. Physiological roles of matrix metalloproteinases: implications for tumor growth and metastasis. Can J Physiol Pharmacol 1999; 77: 465–480
   PubMed Web of Science ®Google Scholar
• Nabeshima K, Inoue T, Shimao Y, Sameshima T. Matrix metalloproteinases in tumor invasion: role for cell migration. Pathol Int 2002; 52: 255–264
   PubMed Web of Science ®Google Scholar
• Primakoff P, Myles D G. The ADAM gene family: surface proteins with adhesion and protease activity. Trends Genet 2000; 16: 83–87
   PubMed Web of Science ®Google Scholar
• White J M. ADAMs: modulators of cell-cell and cell-matrix interactions. Curr Opin Cell Biol 2003; 15: 598–606
   PubMed Web of Science ®Google Scholar
• Apte S S. A disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motifs: the ADAMTS family. Int J Biochem Cell Biol 2004; 36: 981–985
   Web of Science ®Google Scholar
• Huovila A P, Turner A J, Pelto-Huikko M, Karkkainen I, Ortiz R M. Shedding light on ADAM metalloproteinases. Trends Biochem Sci 2005; 30: 413–422
   PubMed Web of Science ®Google Scholar
• Murphy G, Murthy A, Khokha R. Clipping, Shedding and RIPping keeps immunity on cue. Trends Immunol 2007, In press
   Google Scholar
• Tang B L. ADAMTS: a novel family of extracellular matrix proteases. Int J Biochem Cell Biol 2001; 33: 33–44
   PubMed Web of Science ®Google Scholar
• Radisky D C, Levy D D, Littlepage L E, Liu H, Nelson C M, Fata J E, Leake D, Godden E L, Albertson D G, Nieto M A, Werb Z, Bissell M. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature 2005; 436: 123–127
   PubMed Web of Science ®Google Scholar
• Tanner M M, Tirkkonen M, Kallioniemi A, Isola J, Kuukasjarvi T, Collins C, Kowbel D, Guan X Y, Trent J, Gray J W, Meltzer P, Kallioniemi O P. Independent amplification and frequent co-amplification of three nonsyntenic regions on the long arm of chromosome 20 in human breast cancer. Cancer Res 1996; 56: 3441–3445
   PubMedGoogle Scholar
• Grenet J, Valentine V, Kitson J, Li H, Farrow S N, Kidd V J. Duplication of the DR3 gene on human chromosome 1p36 and its deletion in human neuroblastoma. Genomics 1998; 49: 385–393
   PubMedGoogle Scholar
• Gururajan R, Lahti J M, Grenet J, Easton J, Gruber I, Ambros P F, Kidd V J. Duplication of a genomic region containing the Cdc2L1–2 and MMP21–22 genes on human chromosome 1p36.3 and their linkage to D1Z2. Genome Res 1998; 8: 929–939
   PubMedGoogle Scholar
• Rao P H, Cigudosa J C, Ning Y, Calasanz M J, Iida S, Tagawa S, Michaeli J, Klein B, Dalla-Favera R, Jhanwar S C, et al. Multicolor spectral karyotyping identifies new recurring breakpoints and translocations in multiple myeloma. Blood 1998; 92: 1743–1748
   PubMed Web of Science ®Google Scholar
• Llano E, Pendas A M, Freije J P, Nakano A, Knauper V, Murphy G, Lopez-Otin C. Identification and characterization of human MT5-MMP, a new membrane-bound activator of progelatinase a overexpressed in brain tumors. Cancer Res 1999; 59: 2570–2576
   PubMed Web of Science ®Google Scholar
• Fujiwara T, Bandi M, Nitta M, Ivanova E V, Bronson R T, Pellman D. Cytokinesis failure generating tetraploids promotes tumorigenesis in p53-null cells. Nature 2005; 437: 1043–1047
   PubMed Web of Science ®Google Scholar
• Rivat C, Le Floch N, Sabbah M, Teyrol I, Redeuilh G, Bruyneel E, Mareel M, Matrisian L M, Crawford H C, Gespach C, Attoub S. Synergistic cooperation between the AP-1 and LEF-1 transcription factors in activation of the matrilysin promoter by the src oncogene: implications in cellular invasion. FASEB J 2003; 17: 1721–1723
   PubMed Web of Science ®Google Scholar
• Sun Y, Zeng X R, Wenger L, Firestein G S, Cheung H S. P53 down-regulates matrix metalloproteinase-1 by targeting the communications between AP-1 and the basal transcription complex. J Cell Biochem 2004; 92: 258–269
   PubMed Web of Science ®Google Scholar
• Gabison E E, Hoang-Xuan T, Mauviel A, Menashi S. EMMPRIN/CD147, an MMP modulator in cancer, development and tissue repair. Biochimie 2005; 87: 361–368
   PubMed Web of Science ®Google Scholar
• Balbin M, Fueyo A, Tester A M, Pendas A M, Pitiot A S, Astudillo A, Overall C M, Shapiro S D, Lopez-Otin C. Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nat Genet 2003; 35: 252–257
   PubMed Web of Science ®Google Scholar
• Handsley M M, Edwards D R. Metalloproteinases and their inhibitors in tumor angiogenesis. Int J Cancer 2005; 115: 849–860
   PubMed Web of Science ®Google Scholar
• Grutzmann R, Luttges J, Sipos B, Ammerpohl O, Dobrowolski F, Alldinger I, Kersting S, Ockert D, Koch R, Kalthoff H, Schakert H K, Jaeger H D, Kloppel G, Pilarsky C. ADAM9 expression in pancreatic cancer is associated with tumour type and is a prognostic factor in ductal adenocarcinoma. Br J Cancer 2004; 90: 1053–1058
   PubMed Web of Science ®Google Scholar
• Ishikawa N, Daigo Y, Yasui W, Inai K, Nishimura H, Tsuchiya E, Kohno N, Nakamura Y. ADAM8 as a novel serological and histochemical marker for lung cancer. Clin Cancer Res 2004; 10: 8363–8370
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Miyamoto S, Suzuki S O, Oki E, Yagi H, Sonoda K, Yamazaki A, Mizushima H, Maehara Y, Mekada E, Nakano H. Clinical significance of heparin-binding epidermal growth factor-like growth factor and a disintegrin and metalloprotease 17 expression in human ovarian cancer. Clin Cancer Res 2005; 11: 4783–4792
   PubMed Web of Science ®Google Scholar
• Blobel C P. ADAMs: key components in EGFR signalling and development. Nat Rev Mol Cell Biol 2005; 6: 32–43
   PubMed Web of Science ®Google Scholar
• Arribas J, Bech-Serra J J, Santiago-Josefat B. ADAMs, cell migration and cancer. Cancer Metastasis Rev 2006; 25: 57–68
   PubMed Web of Science ®Google Scholar
• Held-Feindt J, Paredes E B, Blomer U, Seidenbecher C, Stark A M, Mehdorn H M, Mentlein R. Matrix-degrading proteases ADAMTS4 and ADAMTS5 (disintegrins and metalloproteinases with thrombospondin motifs 4 and 5) are expressed in human glioblastomas. Int J Cancer 2006; 118: 55–61
   Google Scholar
• Porter S, Span P N, Sweep F C, Tjan-Heijnen V C, Pennington C J, Pedersen T X, Johnsen M, Lund L R, Romer J, Edwards D R. ADAMTS8 and ADAMTS15 expression predicts survival in human breast carcinoma. Int J Cancer 2006; 118: 1241–1247
   PubMed Web of Science ®Google Scholar
• Masui T, Hosotani R, Tsuji S, Miyamoto Y, Yasuda S, Ida J, Nakajima S, Kawaguchi M, Kobayashi H, Koizumi M, et al. Expression of METH-1 and METH-2 in pancreatic cancer. Clin Cancer Res 2001; 7: 3437–3443
   PubMed Web of Science ®Google Scholar
• Kuno K, Bannai K, Hakozaki M, Matsushima K, Hirose K. The carboxyl-terminal half region of ADAMTS-1 suppresses both tumorigenicity and experimental tumor metastatic potential. Biochem Biophys Res Commun 2004; 319: 1327–1333
   Google Scholar
• Lambert E, Boudot C, Kadri Z, Soula-Rothhut M, Sowa M L, Mayeux P, Hornebeck W, Haye B, Petitfrere E. Tissue inhibitor of metalloproteinases-1 signalling pathway leading to erythroid cell survival. Biochem J 2003; 372: 767–774
   PubMed Web of Science ®Google Scholar
• Lambert E, Dasse E, Haye B, Petitfrere E. TIMPs as multifacial proteins. Crit Rev Oncol Hematol 2004; 49: 187–198
   PubMed Web of Science ®Google Scholar
• Gomis-Ruth F X, Maskos K, Betz M, Bergner A, Huber R, Suzuki K, Yoshida N, Nagase H, Brew K, Bourenkov G P, Bartanik H, Bode W. Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP1. Nature 1997; 389: 77–81
   PubMed Web of Science ®Google Scholar
• Fernandez-Catalan C, Bode W, Huber R, Turk D, Calvete J J, Lichte A, Tschesche H, Maskos K. Crystal structure of the complex formed by the membrane type 1-matrix metalloproteinase with the tissue inhibitor of metalloproteinases-2, the soluble progelatinase A receptor. EMBO J 1998; 17: 5238–5248
   PubMed Web of Science ®Google Scholar
• Bode W, Fernandez-Catalan C, Grams F, Gomis-Ruth F X, Nagase H, Tschesche H, Maskos K. Insights into MMP-TIMP interactions. Ann NY Acad Sci 1999; 878: 73–91
   PubMed Web of Science ®Google Scholar
• Mannello F, Gazzanelli G. Tissue inhibitors of metalloproteinases and programmed cell death: conundrums, controversies and potential implications. Apoptosis 2001; 6: 479–482
   PubMed Web of Science ®Google Scholar
• Wei S, Xie Z, Filenova E, Brew K. Drosophila TIMP is a potent inhibitor of MMPs and TACE: similarities in structure and function to TIMP3. Biochemistry 2003; 42: 12200–12207
   Google Scholar
• Lee M H, Maskos K, Knauper V, Dodds P, Murphy G. Mapping and characterization of the functional epitopes of tissue inhibitor of metalloproteinases (TIMP)-3 using TIMP1 as the scaffold: a new frontier in TIMP engineering. Protein Sci 2002; 11: 2493–2503
   PubMed Web of Science ®Google Scholar
• Lee M H, Rapti M, Knauper V, Murphy G. Threonine 98, the pivotal residue of tissue inhibitor of metalloproteinases (TIMP)-1 in metalloproteinase recognition. J Biol Chem 2004; 279: 17562–17569
   PubMed Web of Science ®Google Scholar
• Derry J M, Barnard P J. Physical linkage of the A-raf-1, properdin, synapsin I, and TIMP genes on the human and mouse X chromosomes. Genomics 1992; 12: 632–638
   PubMed Web of Science ®Google Scholar
• Pohar N, Godenschwege T A, Buchner E. Invertebrate tissue inhibitor of metalloproteinase: structure and nested gene organization within the synapsin locus is conserved from Drosophila to human. Genomics 1999; 57: 293–296
   PubMed Web of Science ®Google Scholar
• Rahkonen O P, Koskivirta I M, Oksjoki S M, Jokinen E, Vuorio E I. Characterization of the murine Timp4 gene, localization within intron 5 of the synapsin 2 gene and tissue distribution of the mRNA. Biochim Biophys Acta 2002; 1577: 45–52
   PubMedGoogle Scholar
• Yu W P, Brenner S, Venkatesh B. Duplication, degeneration and subfunctionalization of the nested synapsin-Timp genes in Fugu. Trends Genet 2003; 19: 180–183
   PubMedGoogle Scholar
• d'Ortho M P, Stanton H, Butler M, Atkinson S J, Murphy G, Hembry R M. MT1-MMP on the cell surface causes focal degradation of gelatin films. FEBS Lett 1998; 421: 159–164
   Google Scholar
• Strongin A Y, Collier I, Bannikov G, Marmer B L, Grant G A, Goldberg G I. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem 1995; 270: 5331–5338
   PubMed Web of Science ®Google Scholar
• Amour A, Knight C G, Webster A, Slocombe P M, Stephens P E, Knauper V, Docherty A J, Murphy G. The in vitro activity of ADAM-10 is inhibited by TIMP1 and TIMP3. FEBS Lett 2000; 473: 275–279
   PubMed Web of Science ®Google Scholar
• Kashiwagi M, Tortorella M, Nagase H, Brew K. TIMP3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5). J Biol Chem 2001; 276: 12501–12504
   PubMed Web of Science ®Google Scholar
• Yu W H, Yu S, Meng Q, Brew K, Woessner J F, Jr. TIMP3 binds to sulfated glycosaminoglycans of the extracellular matrix. J Biol Chem 2000; 275: 31226–31232
   PubMed Web of Science ®Google Scholar
• Weber B H, Vogt G, Pruett R C, Stohr H, Felbor U. Mutations in the tissue inhibitor of metalloproteinases-3 (TIMP3) in patients with Sorsby's fundus dystrophy. Nat Genet 1994; 8: 352–356
   PubMed Web of Science ®Google Scholar
• Langton K P, McKie N, Curtis A, Goodship J A, Bond P M, Barker M D, Clarke M. A novel tissue inhibitor of metalloproteinases-3 mutation reveals a common molecular phenotype in Sorsby's fundus dystrophy. J Biol Chem 2000; 275: 27027–27031
   Google Scholar
• Yeow K M, Kishnani N S, Hutton M, Hawkes S P, Murphy G, Edwards D R. Sorsby's fundus dystrophy tissue inhibitor of metalloproteinases-3 (TIMP3) mutants have unimpaired matrix metalloproteinase inhibitory activities, but affect cell adhesion to the extracellular matrix. Matrix Biol 2002; 21: 75–88
   Google Scholar
• Nuttall R K, Sampieri C L, Pennington C J, Gill S E, Schultz G A, Edwards D R. Expression analysis of the entire MMP and TIMP gene families during mouse tissue development. FEBS Lett 2004; 563: 129–134
   PubMed Web of Science ®Google Scholar
• Bachman K E, Herman J G, Corn P G, Merlo A, Costello J F, Cavenee W K, Baylin S B, Graff J R. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res 1999; 59: 798–802
   PubMed Web of Science ®Google Scholar
• Ivanova T, Vinokurova S, Petrenko A, Eshilev E, Solovyova N, Kisseljov F, Kisseljova N. Frequent hypermethylation of 5′ flanking region of TIMP2 gene in cervical cancer. Int J Cancer 2004; 108: 882–886
   PubMed Web of Science ®Google Scholar
• Dammann R, Strunnikova M, Schagdarsurengin U, Rastetter M, Papritz M, Hattenhorst U E, Hofmann H S, Silber R E, Burdach S, Hansen G. CpG island methylation and expression of tumour-associated genes in lung carcinoma. Eur J Cancer 2005; 41: 1223–1236
   PubMed Web of Science ®Google Scholar
• Roten L, Nemoto S, Simsic J, Coker M L, Rao V, Baicu S, Defreyte G, Soloway P J, Zile M R, Spinale F G. Effects of gene deletion of the tissue inhibitor of the matrix metalloproteinase-type 1 (TIMP1) on left ventricular geometry and function in mice. J Mol Cell Cardiol 2000; 32: 109–120
   PubMed Web of Science ®Google Scholar
• Creemers E E, Davis J N, Parkhurst A M, Leenders P, Dowdy K B, Hapke E, Hauet A M, Escobar P G, Cleutjens J P, Smits J F, Daemen M J, Zile M R, Spinale F G. Deficiency of TIMP1 exacerbates LV remodeling after myocardial infarction in mice. Am J Physiol Heart Circ Physiol 2003; 284: H364–H371
   PubMed Web of Science ®Google Scholar
• Ikonomidis J S, Hendrick J W, Parkhurst A M, Herron A R, Escobar P G, Dowdy K B, Stroud R E, Hapke E, Zile M R, Spinale F G. Accelerated LV remodeling after myocardial infarction in TIMP1-deficient mice: effects of exogenous MMP inhibition. Am J Physiol Heart Circ Physiol 2005; 288: H149–158
   PubMed Web of Science ®Google Scholar
• Kassiri Z, Khokha R. Myocardial extra-cellular matrix and its regulation by metalloproteinases and their inhibitors. Thromb Haemost 2005; 93: 212–219
   PubMed Web of Science ®Google Scholar
• Koskivirta I, Cruz-Munoz W, Khokha R, Vuorio E. Characterization of Timp4 deficient mice, Manuscript in preparation
   Google Scholar
• Cruz-Munoz W, Sanchez O H, Di Grappa M, English J L, Hill R P, Khokha R. Enhanced metastatic dissemination to multiple organs by melanoma and lymphoma cells in timp3-/-mice. Oncogene 2006; 25: 6489–6496
   Google Scholar
• Hammani K, Blakis A, Morsette D, Bowcock A M, Schmutte C, Henriet P, DeClerck Y A. Structure and characterization of the human tissue inhibitor of metalloproteinases-2 gene. J Biol Chem 1996; 271: 25498–25505
   PubMed Web of Science ®Google Scholar
• Sun Y, Hegamyer G, Kim H, Sithanandam K, Li H, Watts R, Colburn N H. Molecular cloning of mouse tissue inhibitor of metalloproteinases-3 and its promoter. Specific lack of expression in neoplastic JB6 cells may reflect altered gene methylation. J Biol Chem 1995; 270: 19312–19319
   PubMed Web of Science ®Google Scholar
• Young D A, Phillips B W, Lundy C, Nuttall R K, Hogan A, Schultz G A, Leco K J, Clark I M, Edwards D R. Identification of an initiator-like element essential for the expression of the tissue inhibitor of metalloproteinases-4 (Timp4) gene. Biochem J 2002; 364: 89–99
   PubMed Web of Science ®Google Scholar
• Smookler D S, Mohammed F F, Kassiri Z, Duncan G S, Mak T W, Khokha R. Tissue inhibitor of metalloproteinase 3 regulates TNF-dependent systemic inflammation. J Immunol 2006; 176: 721–725
   PubMed Web of Science ®Google Scholar
• Troeberg L, Tanaka M, Wait R, Shi Y E, Brew K, Nagase H. E. coli expression of TIMP4 and comparative kinetic studies with TIMP1 and TIMP2: insights into the interactions of TIMPs and matrix metalloproteinase 2 (gelatinase A). Biochemistry 2002; 41: 15025–15035
   PubMed Web of Science ®Google Scholar
• Ree A H, Florenes V A, Berg J P, Maelandsmo G M, Nesland J M, Fodstad O. High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP1 and TIMP2) in primary breast carcinomas are associated with development of distant metastases. Clin Cancer Res 1997; 3: 1623–1628
   PubMed Web of Science ®Google Scholar
• Airola K, Karonen T, Vaalamo M, Lehti K, Lohi J, Kariniemi A L, Keski-Oja J, Saarialho-Kere U K. Expression of collagenases-1 and-3 and their inhibitors TIMP1 and-3 correlates with the level of invasion in malignant melanomas. Br J Cancer 1999; 80: 733–743
   PubMed Web of Science ®Google Scholar
• Thomas P, Khokha R, Shepherd F A, Feld R, Tsao M S. Differential expression of matrix metalloproteinases and their inhibitors in non-small cell lung cancer. J Pathol 2000; 190: 150–156
   PubMed Web of Science ®Google Scholar
• Cho K R, Vogelstein B. Genetic alterations in the adenoma–carcinoma sequence. Cancer 1992; 70: 1727–1731
   PubMed Web of Science ®Google Scholar
• Michor F, Iwasa Y, Vogelstein B, Lengauer C, Nowak M A. Can chromosomal instability initiate tumorigenesis?. Semin Cancer Biol 2005; 15: 43–49
   PubMedGoogle Scholar
• Masson R, Lefebvre O, Noel A, Fahime M E, Chenard M P, Wendling C, Kebers F, LeMeur M, Dierich A, Foidart J M, Bassett P, Rio M C. In vivo evidence that the stromelysin-3 metalloproteinase contributes in a paracrine manner to epithelial cell malignancy. J Cell Biol 1998; 140: 1535–1541
   PubMed Web of Science ®Google Scholar
• Wilson C L, Heppner K J, Labosky P A, Hogan B L, Matrisian L M. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc Natl Acad Sci USA 1997; 94: 1402–1407
   PubMed Web of Science ®Google Scholar
• Nigro J M, Aldape K D, Hess S M, Tlsty T D. Cellular adhesion regulates p53 protein levels in primary human keratinocytes. Cancer Res 1997; 57: 3635–3639
   PubMedGoogle Scholar
• Tlsty T D. Cell-adhesion-dependent influences on genomic instability and carcinogenesis. Curr Opin Cell Biol 1998; 10: 647–653
   Google Scholar
• Noe V, Fingleton B, Jacobs K, Crawford H C, Vermeulen S, Steelant W, Bruyneel E, Matrisian L M, Mareel M. Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci 2001; 114: 111–118
   PubMed Web of Science ®Google Scholar
• Sternlicht M D, Lochter A, Sympson C J, Huey B, Rougier J P, Gray J W, Pinkel D, Bissell M J, Werb Z. The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell 1999; 98: 137–146
   PubMed Web of Science ®Google Scholar
• Khokha R, Waterhouse P, Yagel S, Lala P K, Overall C M, Norton G, Denhardt D T. Antisense RNA-induced reduction in murine TIMP levels confers oncogenicity on Swiss 3T3 cells. Science 1989; 243: 947–950
   PubMed Web of Science ®Google Scholar
• Khokha R, Waterhouse P, Lala P, Zimmer M, Denhardt D T. Increased proteinase expression during tumor progression of cell lines down-modulated for TIMP levels: a new transformation paradigm? [corrected]. J Cancer Res Clin Oncol 1991; 117: 333–338
   Google Scholar
• Rhee J S, Diaz R, Korets L, Hodgson J G, Coussens L M. TIMP1 alters susceptibility to carcinogenesis. Cancer Res 2004; 64: 952–961
   PubMed Web of Science ®Google Scholar
• Orr F W, Kostenuik P, Sanchez-Sweatman O H, Singh G. Mechanisms involved in the metastasis of cancer to bone. Breast Cancer Res Treat 1993; 25: 151–163
   Google Scholar
• Edwards D R, Waterhouse P, Holman M L, Denhardt D T. A growth-responsive gene (16C8) in normal mouse fibroblasts homologous to a human collagenase inhibitor with erythroid-potentiating activity: evidence for inducible and constitutive transcripts. Nucleic Acids Res 1986; 14: 8863–8878
   PubMedGoogle Scholar
• Zhao W Q, Li H, Yamashita K, Guo X K, Hoshino T, Yoshida S, Shinya T, Hayakawa T. Cell cycle-associated accumulation of tissue inhibitor of metalloproteinases-1 (TIMP1) in the nuclei of human gingival fibroblasts. J Cell Sci 1998; 111: 1147–1153
   PubMedGoogle Scholar
• Martin D C, Ruther U, Sanchez-Sweatman O H, Orr F W, Khokha R. Inhibition of SV40 T antigen-induced hepatocellular carcinoma in TIMP1 transgenic mice. Oncogene 1996; 13: 569–576
   PubMed Web of Science ®Google Scholar
• Buck T B, Yoshiji H, Harris S R, Bunce O R, Thorgeirsson U P. The effects of sustained elevated levels of circulating tissue inhibitor of metalloproteinases-1 on the development of breast cancer in mice. Ann N Y Acad Sci 1999; 878: 732–735
   Google Scholar
• Khokha R. Suppression of the tumorigenic and metastatic abilities of murine B16-F10 melanoma cells in vivo by the overexpression of the tissue inhibitor of the metalloproteinases-1. J Natl Cancer Inst 1994; 86: 299–304
   PubMed Web of Science ®Google Scholar
• Wang M, Liu Y E, Greene J, Sheng S, Fuchs A, Rosen E M, Shi Y E. Inhibition of tumor growth and metastasis of human breast cancer cells transfected with tissue inhibitor of metalloproteinase 4. Oncogene 1997; 14: 2767–2774
   PubMedGoogle Scholar
• Vergani V, Garofalo A, Bani M R, Borsotti P, Parker M P, Drudis T, Mazzarol G, Viale G, Giavazzi R, Stetler-Stevenson W G, Taraboletti G. Inhibition of matrix metalloproteinases by over-expression of tissue inhibitor of metalloproteinase-2 inhibits the growth of experimental hemangiomas. Int J Cancer 2001; 91: 241–247
   Google Scholar
• Spurbeck W W, Ng C Y, Strom T S, Vanin E F, Davidoff A M. Enforced expression of tissue inhibitor of matrix metalloproteinase-3 affects functional capillary morphogenesis and inhibits tumor growth in a murine tumor model. Blood 2002; 100: 3361–3368
   PubMed Web of Science ®Google Scholar
• Nakopoulou L, Katsarou S, Giannopoulou I, Alexandrou P, Tsirmpa I, Panayotopoulou E, Mavrommatis J, Keramopoulos A. Correlation of tissue inhibitor of metalloproteinase-2 with proliferative activity and patients' survival in breast cancer. Mod Pathol 2002; 15: 26–34
   PubMed Web of Science ®Google Scholar
• Nakopoulou L, Giannopoulou I, Lazaris A, Alexandrou P, Tsirmpa I, Markaki S, Panayotopoulou E, Keramopoulos A. The favorable prognostic impact of tissue inhibitor of matrix metalloproteinases-1 protein overexpression in breast cancer cells. APMIS 2003; 111: 1027–1036
   PubMed Web of Science ®Google Scholar
• Miyazaki T, Kato H, Nakajima M, Faried A, Takita J, Sohda M, Fukai Y, Yamaguchi S, Masuda N, Manda R, et al. An immunohistochemical study of TIMP3 expression in oesophageal squamous cell carcinoma. Br J Cancer 2004; 91: 1556–1560
   Google Scholar
• Gakiopoulou H, Nakopoulou L, Siatelis A, Mavrommatis I, Panayotopoulou E G, Tsirmpa I, Stravodimos C, Giannopoulos A. Tissue inhibitor of metalloproteinase-2 as a multifunctional molecule of which the expression is associated with adverse prognosis of patients with urothelial bladder carcinomas. Clin Cancer Res 2003; 9: 5573–5581
   PubMed Web of Science ®Google Scholar
• Karavasilis V, Malamou-Mitsi V, Briasoulis E, Tsanou E, Kitsou E, Kalofonos H, Fountzilas G, Fotsis T, Pavlidis N. Matrix metalloproteinases in carcinoma of unknown primary. Cancer 2005; 104: 2282–2287
   PubMed Web of Science ®Google Scholar
• Ruokolainen H, Paakko P, Turpeenniemi-Hujanen T. Tissue inhibitor of matrix metalloproteinase-1 is prognostic in head and neck squamous cell carcinoma: comparison of the circulating and tissue immunoreactive protein. Clin Cancer Res 2005; 11: 3257–3264
   PubMed Web of Science ®Google Scholar
• Hayakawa T, Yamashita K, Kishi J, Harigaya K. Tissue inhibitor of metalloproteinases from human bone marrow stromal cell line KM 102 has erythroid-potentiating activity, suggesting its possibly bifunctional role in the hematopoietic microenvironment. FEBS Lett 1990; 268: 125–128
   Google Scholar
• Murate T, Yamashita K, Ohashi H, Kagami Y, Tsushita K, Kinoshita T, Hotta T, Saito H, Yoshida S, Mori K J, et al. Erythroid potentiating activity of tissue inhibitor of metalloproteinases on the differentiation of erythropoietin-responsive mouse erythroleukemia cell line, ELM-I-1–3, is closely related to its cell growth potentiating activity. Exp Hematol 1993; 21: 169–176
   PubMedGoogle Scholar
• Hayakawa T, Yamashita K, Ohuchi E, Shinagawa A. Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP2). J Cell Sci 1994; 107: 2373–2379, (Pt 9)
   PubMed Web of Science ®Google Scholar
• Chesler L, Golde D W, Bersch N, Johnson M D. Metalloproteinase inhibition and erythroid potentiation are independent activities of tissue inhibitor of metalloproteinases-1. Blood 1995; 86: 4506–4515
   PubMed Web of Science ®Google Scholar
• Forough R, Koyama N, Hasenstab D, Lea H, Clowes M, Nikkari S T, Clowes A W. Overexpression of tissue inhibitor of matrix metalloproteinase-1 inhibits vascular smooth muscle cell functions in vitro and in vivo. Circ Res 1996; 79: 812–820
   PubMed Web of Science ®Google Scholar
• Saika S, Kawashima Y, Okada Y, Tanaka S I, Yamanaka O, Ohnishi Y, Ooshima A. Recombinant TIMP1 and-2 enhance the proliferation of rabbit corneal epithelial cells in vitro and the spreading of rabbit corneal epithelium in situ. Curr Eye Res 1998; 17: 47–52
   PubMed Web of Science ®Google Scholar
• Fata J E, Leco K J, Moorehead R A, Martin D C, Khokha R. Timp1 is important for epithelial proliferation and branching morphogenesis during mouse mammary development. Dev Biol 1999; 211: 238–254
   PubMedGoogle Scholar
• Luparello C, Avanzato G, Carella C, Pucci-Minafra I. Tissue inhibitor of metalloprotease (TIMP)-1 and proliferative behaviour of clonal breast cancer cells. Breast Cancer Res Treat 1999; 54: 235–244
   PubMed Web of Science ®Google Scholar
• Martin D C, Fowlkes J L, Babic B, Khokha R. Insulin-like growth factor II signaling in neoplastic proliferation is blocked by transgenic expression of the metalloproteinase inhibitor TIMP1. J Cell Biol 1999; 146: 881–892
   PubMed Web of Science ®Google Scholar
• Petitfrere E, Kadri Z, Boudot C, Sowa M L, Mayeux P, Haye B, Billat C. Involvement of the p38 mitogen-activated protein kinase pathway in tissue inhibitor of metalloproteinases-1-induced erythroid differentiation. FEBS Lett 2000; 485: 117–121
   Google Scholar
• Wang T, Yamashita K, Iwata K, Hayakawa T. Both tissue inhibitors of metalloproteinases-1 (TIMP1) and TIMP2 activate Ras but through different pathways. Biochem Biophys Res Commun 2002; 296: 201–205
   PubMedGoogle Scholar
• van der Laan W H, Quax P H, Seemayer C A, Huisman L G, Pieterman E J, Grimbergen J M, Verheijen J H, Breedveld F C, Gay R E, Gay S, Huizinga T W, Pap I. Cartilage degradation and invasion by rheumatoid synovial fibroblasts is inhibited by gene transfer of TIMP1 and TIMP3. Gene Ther 2003; 10: 234–242
   PubMedGoogle Scholar
• Akahane T, Akahane M, Shah A, Thorgeirsson U P. TIMP1 stimulates proliferation of human aortic smooth muscle cells and Ras effector pathways. Biochem Biophys Res Commun 2004; 324: 440–445
   PubMedGoogle Scholar
• Djafarzadeh R, Mojaat A, Vicente A B, von Luttichau I, Nelson P J. Exogenously added GPI-anchored tissue inhibitor of matrix metalloproteinase-1 (TIMP1) displays enhanced and novel biological activities. Biol Chem 2004; 385: 655–663
   PubMed Web of Science ®Google Scholar
• Haviernik P, Lahoda C, Bradley H L, Hawley T S, Ramezani A, Hawley R G, Stetler-Stevenson M, Stetler-Stevenson W G, Bunting K D. Tissue inhibitor of matrix metalloproteinase-1 overexpression in M1 myeloblasts impairs IL-6-induced differentiation. Oncogene 2004; 23: 9212–9219
   Google Scholar
• Porter J F, Shen S, Denhardt D T. Tissue inhibitor of metalloproteinase-1 stimulates proliferation of human cancer cells by inhibiting a metalloproteinase. Br J Cancer 2004; 90: 463–470
   PubMed Web of Science ®Google Scholar
• Lovelock J D, Baker A H, Gao F, Dong J F, Bergeron A L, McPheat W, Sivasubramanian N, Mann D L. Heterogeneous effects of tissue inhibitors of matrix metalloproteinases on cardiac fibroblasts. Am J Physiol Heart Circ Physiol 2005; 288: H461–468
   PubMed Web of Science ®Google Scholar
• Mohammed F F, Pennington C J, Kassiri Z, Rubin J S, Soloway P D, Ruther U, Edwards D R, Khokha R. Metalloproteinase inhibitor TIMP1 affects hepatocyte cell cycle via HGF activation in murine liver regeneration. Hepatology 2005; 41: 857–867
   PubMed Web of Science ®Google Scholar
• Nishimura K, Yamashita K, Kato Y, Iwata T, Iwata K, Nishikawa T, Goto S, Hayakawa T. Inhibitory activity on matrix metalloproteinases and cell-proliferating activity of tissue inhibitor of metalloproteinases-1 (TIMP1)-contrastive difference between human and bovine TIMP1s on mouse cell proliferation. Growth Factors 2005; 23: 135–142
   PubMed Web of Science ®Google Scholar
• Murphy A N, Unsworth E J, Stetler-Stevenson W G. Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. J Cell Physiol 1993; 157: 351–358
   PubMed Web of Science ®Google Scholar
• Corcoran M L, Stetler-Stevenson W G. Tissue inhibitor of metalloproteinase-2 stimulates fibroblast proliferation via a cAMP-dependent mechanism. J Biol Chem 1995; 270: 13453–13459
   PubMed Web of Science ®Google Scholar
• Baker A H, Zaltsman A B, George S J, Newby A C. Divergent effects of tissue inhibitor of metalloproteinase-1,-2, or-3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP3 promotes apoptosis. J Clin Invest 1998; 101: 1478–1487
   PubMed Web of Science ®Google Scholar
• Valente P, Fassina G, Melchiori A, Masiello L, Cilli M, Vacca A, Onisto M, Santi L, Stetler-Stevenson W G, Albini A. TIMP2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. Int J Cancer 1998; 75: 246–253
   PubMed Web of Science ®Google Scholar
• Wingfield P T, Sax J K, Stahl S J, Kaufman J, Palmer I, Chung V, Corcoran M L, Kleiner D E, Stetler-Stevenson W G. Biophysical and functional characterization of full-length, recombinant human tissue inhibitor of metalloproteinases-2 (TIMP2) produced in Escherichia coli. Comparison of wild type and amino-terminal alanine appended variant with implications for the mechanism of TIMP functions. J Biol Chem 1999; 274: 21362–21368
   PubMed Web of Science ®Google Scholar
• Hoegy S E, Oh H R, Corcoran M L, Stetler-Stevenson W G. Tissue inhibitor of metalloproteinases-2 (TIMP2) suppresses TKR-growth factor signaling independent of metalloproteinase inhibition. J Biol Chem 2001; 276: 3203–3214
   PubMed Web of Science ®Google Scholar
• Fernandez C A, Butterfield C, Jackson G, Moses M A. Structural and functional uncoupling of the enzymatic and angiogenic inhibitory activities of tissue inhibitor of metalloproteinase-2 (TIMP2): loop 6 is a novel angiogenesis inhibitor. J Biol Chem 2003; 278: 40989–40995
   Web of Science ®Google Scholar
• Seo D W, Li H, Guedez L, Wingfield P T, Diaz T, Salloum R, Wei B Y, Stetler-Stevenson W G. TIMP2 mediated inhibition of angiogenesis: an MMP-independent mechanism. Cell 2003; 114: 171–180
   PubMed Web of Science ®Google Scholar
• Lizarraga F, Maldonado V, Melendez-Zajgla J. Tissue inhibitor of metalloproteinases-2 growth-stimulatory activity is mediated by nuclear factor-kappa B in A549 lung epithelial cells. Int J Biochem Cell Biol 2004; 36: 1655–1663
   Google Scholar
• Perez-Martinez L, Jaworski D M. Tissue inhibitor of metalloproteinase-2 promotes neuronal differentiation by acting as an anti-mitogenic signal. J Neurosci 2005; 25: 4917–4929
   PubMed Web of Science ®Google Scholar
• Yang T T, Hawkes S P. Role of the 21-kDa protein TIMP3 in oncogenic transformation of cultured chicken embryo fibroblasts. Proc Natl Acad Sci USA 1992; 89: 10676–10680
   PubMed Web of Science ®Google Scholar
• Castagnino P, Soriano J V, Montesano R, Bottaro D P. Induction of tissue inhibitor of metalloproteinases-3 is a delayed early cellular response to hepatocyte growth factor. Oncogene 1998; 17: 481–492
   PubMed Web of Science ®Google Scholar
• Celiker M Y, Wang M, Atsidaftos E, Liu X, Liu Y E, Jiang Y, Valderrama E, Goldberg I D, Shi Y E. Inhibition of Wilms' tumor growth by intramuscular administration of tissue inhibitor of metalloproteinases-4 plasmid DNA. Oncogene 2001; 20: 4337–4343
   PubMed Web of Science ®Google Scholar
• Mohammed F F, Khokha R. Thinking outside the cell: proteases regulate hepatocyte division. Trends Cell Biol 2005; 15: 555–563
   PubMed Web of Science ®Google Scholar
• Montgomery A M, Mueller B M, Reisfeld R A, Taylor S M, DeClerck Y A. Effect of tissue inhibitor of the matrix metalloproteinases-2 expression on the growth and spontaneous metastasis of a human melanoma cell line. Cancer Res 1994; 54: 5467–5473
   PubMed Web of Science ®Google Scholar
• Henriet P, Zhong Z D, Brooks P C, Weinberg K I, DeClerck Y A. Contact with fibrillar collagen inhibits melanoma cell proliferation by up-regulating p27KIP1. Proc Natl Acad Sci USA 2000; 97: 10026–10031
   PubMed Web of Science ®Google Scholar
• Bian J, Wang Y, Smith M R, Kim H, Jacobs C, Jackman J, Kung H F, Colburn N H, Sun Y. Suppression of in vivo tumor growth and induction of suspension cell death by tissue inhibitor of metalloproteinases (TIMP)-3. Carcinogenesis 1996; 17: 1805–1811
   PubMed Web of Science ®Google Scholar
• Tran P L, Vigneron J P, Pericat D, Dubois S, Cazals D, Hervy M, DeClerck Y A, Degott C, Auclair C. Gene therapy for hepatocellular carcinoma using non-viral vectors composed of bis guanidinium-tren-cholesterol and plasmids encoding the tissue inhibitors of metalloproteinases TIMP2 and TIMP3. Cancer Gene Ther 2003; 10: 435–444
   PubMed Web of Science ®Google Scholar
• Smith M R, Kung H, Durum S K, Colburn N H, Sun Y. TIMP3 induces cell death by stabilizing TNF-alpha receptors on the surface of human colon carcinoma cells. Cytokine 1997; 9: 770–780
   PubMed Web of Science ®Google Scholar
• Stetler-Stevenson W G, Bersch N, Golde D W. Tissue inhibitor of metalloproteinase-2 (TIMP2) has erythroid-potentiating activity. FEBS Lett 1992; 296: 231–234
   PubMed Web of Science ®Google Scholar
• Hayakawa T, Yamashita K, Tanzawa K, Uchijima E, Iwata K. Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett 1992; 298: 29–32
   PubMed Web of Science ®Google Scholar
• Nemeth J A, Goolsby C L. TIMP2, a growth-stimulatory protein from SV40-transformed human fibroblasts. Exp Cell Res 1993; 207: 376–382
   PubMed Web of Science ®Google Scholar
• Yamashita K, Suzuki M, Iwata H, Koike T, Hamaguchi M, Shinagawa A, Noguchi T, Hayakawa T. Tyrosine phosphorylation is crucial for growth signaling by tissue inhibitors of metalloproteinases (TIMP1 and TIMP2). FEBS Lett 1996; 396: 103–107
   PubMed Web of Science ®Google Scholar
• Mori M, Mimori K, Sadanaga N, Inoue H, Tanaka Y, Mafune K, Ueo H, Barnard G F. Prognostic impact of tissue inhibitor of matrix metalloproteinase-1 in esophageal carcinoma. Int J Cancer 2000; 88: 575–578
   Google Scholar
• Remacle A, McCarthy K, Noel A, Maguire T, McDermott E, O'Higgins N, Foidart J M, Duffy M J. High levels of TIMP2 correlate with adverse prognosis in breast cancer. Int J Cancer 2000; 89: 118–121
   PubMed Web of Science ®Google Scholar
• Yano A, Nakamoto T, Hashimoto K, Usui T. Localization and expression of tissue inhibitor of metalloproteinase-1 in human urothelial cancer. J Urol 2002; 167: 729–734
   PubMedGoogle Scholar
• Tunuguntla R, Ripley D, Sang Q X, Chegini N. Expression of matrix metalloproteinase-26 and tissue inhibitors of metalloproteinases TIMP3 and-4 in benign endometrium and endometrial cancer. Gynecol Oncol 2003; 89: 453–459
   PubMed Web of Science ®Google Scholar
• Guedez L, McMarlin A J, Kingma D W, Bennett T A, Stetler-Stevenson M, Stetler-Stevenson W G. Tissue inhibitor of metalloproteinase-1 alters the tumorigenicity of Burkitt's lymphoma via divergent effects on tumor growth and angiogenesis. Am J Pathol 2001; 158: 1207–1215
   PubMed Web of Science ®Google Scholar
• Qi J H, Ebrahem Q, Moore N, Murphy G, Claesson-Welsh L, Bond M, Baker A, Anand-Apte B. A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med 2003; 9: 407–415
   PubMed Web of Science ®Google Scholar
• Reddig P J, Juliano R L. Clinging to life: cell to matrix adhesion and cell survival. Cancer Metastasis Rev 2005; 24: 425–439
   PubMed Web of Science ®Google Scholar
• McKenzie S, Kyprianou N. Apoptosis evasion: the role of survival pathways in prostate cancer progression and therapeutic resistance. J Cell Biochem 2006; 97: 18–32
   PubMed Web of Science ®Google Scholar
• Alexander C M, Howard E W, Bissell M J, Werb Z. Rescue of mammary epithelial cell apoptosis and entactin degradation by a tissue inhibitor of metalloproteinases-1 transgene. J Cell Biol 1996; 135: 1669–1677
   PubMed Web of Science ®Google Scholar
• Guedez L, Stetler-Stevenson W G, Wolff L, Wang J, Fukushima P, Mansoor A, Stetler-Stevenson M. In vitro suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. J Clin Invest 1998; 102: 2002–2010
   PubMed Web of Science ®Google Scholar
• Li G, Fridman R, Kim H R. Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells. Cancer Res 1999; 59: 6267–6275
   PubMed Web of Science ®Google Scholar
• Bloomston M, Shafii A, Zervos E E, Rosemurgy A S. TIMP1 overexpression in pancreatic cancer attenuates tumor growth, decreases implantation and metastasis, and inhibits angiogenesis. J Surg Res 2002; 102: 39–44
   PubMed Web of Science ®Google Scholar
• Lin H, Chen X, Wang J, Yu Z. Inhibition of apoptosis in rat mesangial cells by tissue inhibitor of metalloproteinase-1. Kidney Int 2002; 62: 60–69
   Google Scholar
• Murphy F R, Issa R, Zhou X, Ratnarajah S, Nagase H, Arthur M J, Benyon C, Iredale J P. Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis. J Biol Chem 2002; 277: 11069–11076
   PubMed Web of Science ®Google Scholar
• Oelmann E, Herbst H, Zuhlsdorf M, Albrecht O, Nolte A, Schmitmann C, Manzke O, Diehl V, Stein H, Berdel W E. Tissue inhibitor of metalloproteinases 1 is an autocrine and paracrine survival factor, with additional immune-regulatory functions, expressed by Hodgkin/Reed-Sternberg cells. Blood 2002; 99: 258–267
   PubMed Web of Science ®Google Scholar
• Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, Tsujinoue H, Yanase K, Namisaki T, Imazu H, Fukui H. Tissue inhibitor of metalloproteinases-1 attenuates spontaneous liver fibrosis resolution in the transgenic mouse. Hepatology 2002; 36: 850–860
   PubMed Web of Science ®Google Scholar
• Lee S J, Yoo H J, Bae Y S, Kim H J, Lee S T. TIMP1 inhibits apoptosis in breast carcinoma cells via a pathway involving pertussis toxin-sensitive G protein and c-Src. Biochem Biophys Res Commun 2003; 312: 1196–1201
   PubMed Web of Science ®Google Scholar
• Liu X W, Bernardo M M, Fridman R, Kim H R. Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells against intrinsic apoptotic cell death via the focal adhesion kinase/phosphatidylinositol 3-kinase and MAPK signaling pathway. J Biol Chem 2003; 278: 40364–40372
   PubMed Web of Science ®Google Scholar
• Boulday G, Fitau J, Coupel S, Soulillou J P, Charreau B. Exogenous tissue inhibitor of metalloproteinase-1 promotes endothelial cell survival through activation of the phosphatidylinositol 3-kinase/Akt pathway. Ann N Y Acad Sci 2004; 1030: 28–36
   Web of Science ®Google Scholar
• Chromek M, Tullus K, Lundahl J, Brauner A. Tissue inhibitor of metalloproteinase 1 activates normal human granulocytes, protects them from apoptosis, and blocks their transmigration during inflammation. Infect Immun 2004; 72: 82–88
   PubMed Web of Science ®Google Scholar
• Murphy F, Waung J, Collins J, Arthur M J, Nagase H, Mann D, Benyon R C, Iredale J P. N-Cadherin cleavage during activated hepatic stellate cell apoptosis is inhibited by tissue inhibitor of metalloproteinase-1. Comp Hepatol 2004; 3(Suppl 1)S8
   PubMedGoogle Scholar
• Vorotnikova E, Tries M, Braunhut S. Retinoids and TIMP1 prevent radiation-induced apoptosis of capillary endothelial cells. Radiat Res 2004; 161: 174–184
   PubMed Web of Science ®Google Scholar
• Liu X W, Taube M E, Jung K K, Dong Z, Lee Y J, Roshy S, Sloane B F, Fridman R, Kim H R. Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells from extrinsic cell death: a potential oncogenic activity of tissue inhibitor of metalloproteinase-1. Cancer Res 2005; 65: 898–906
   PubMed Web of Science ®Google Scholar
• Lim M S, Guedez L, Stetler-Stevenson W G, Stetler-Stevenson M. Tissue inhibitor of metalloproteinase-2 induces apoptosis in human T lymphocytes. Ann N Y Acad Sci 1999; 878: 522–523
   PubMed Web of Science ®Google Scholar
• Ahonen M, Baker A H, Kahari V M. Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinases-3 inhibits invasion and induces apoptosis in melanoma cells. Cancer Res 1998; 58: 2310–2315
   PubMed Web of Science ®Google Scholar
• Baker A H, George S J, Zaltsman A B, Murphy G, Newby A C. Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP3. Br J Cancer 1999; 79: 1347–1355
   PubMed Web of Science ®Google Scholar
• Bond M, Murphy G, Bennett M R, Amour A, Knauper V, Newby A C, Baker A H. Localization of the death domain of tissue inhibitor of metalloproteinase-3 to the N terminus. Metalloproteinase inhibition is associated with proapoptotic activity. J Biol Chem 2000; 275: 41358–41363
   PubMed Web of Science ®Google Scholar
• George S J, Lloyd C T, Angelini G D, Newby A C, Baker A H. Inhibition of late vein graft neointima formation in human and porcine models by adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-3. Circulation 2000; 101: 296–304
   PubMed Web of Science ®Google Scholar
• Fata J E, Leco K J, Voura E B, Yu H Y, Waterhouse P, Murphy G, Moorehead R A, Khokha R. Accelerated apoptosis in the Timp3-deficient mammary gland. J Clin Invest 2001; 108: 831–841
   PubMed Web of Science ®Google Scholar
• Bond M, Murphy G, Bennett M R, Newby A C, Baker A H. Tissue inhibitor of metalloproteinase-3 induces a Fas-associated death domain-dependent type II apoptotic pathway. J Biol Chem 2002; 277: 13787–13795
   PubMed Web of Science ®Google Scholar
• Majid M A, Smith V A, Easty D L, Baker A H, Newby A C. Adenovirus mediated gene delivery of tissue inhibitor of metalloproteinases-3 induces death in retinal pigment epithelial cells. Br J Ophthalmol 2002; 86: 97–101
   Google Scholar
• Ahonen M, Poukkula M, Baker A H, Kashiwagi M, Nagase H, Eriksson J E, Kahari V M. Tissue inhibitor of metalloproteinases-3 induces apoptosis in melanoma cells by stabilization of death receptors. Oncogene 2003; 22: 2121–2134
   PubMed Web of Science ®Google Scholar
• Drynda A, Quax P H, Neumann M, van der Laan W H, Pap G, Drynda S, Meinecke I, Kekow J, Neumann W, Huizinga T W, Naumann M, Konig W, Pap T. Gene transfer of tissue inhibitor of metalloproteinases-3 reverses the inhibitory effects of TNF-alpha on Fas-induced apoptosis in rheumatoid arthritis synovial fibroblasts. J Immunol 2005; 174: 6524–6531
   Google Scholar
• Jiang Y, Wang M, Celiker M Y, Liu Y E, Sang Q X, Goldberg I D, Shi Y E. Stimulation of mammary tumorigenesis by systemic tissue inhibitor of matrix metalloproteinase 4 gene delivery. Cancer Res 2001; 61: 2365–2370
   PubMed Web of Science ®Google Scholar
• Tummalapalli C M, Heath B J, Tyagi S C. Tissue inhibitor of metalloproteinase-4 instigates apoptosis in transformed cardiac fibroblasts. J Cell Biochem 2001; 80: 512–521
   PubMed Web of Science ®Google Scholar
• Jung K K, Liu X W, Chirco R, Fridman R, Kim H R. Identification of CD63 as a tissue inhibitor of metalloproteinase-1 interacting cell surface protein. EMBO J 2006; 25: 3934–3942
   PubMed Web of Science ®Google Scholar
• Ahonen M, Ala-Aho R, Baker A H, George S J, Grenman R, Saarialho-Kere U, Kahari V M. Antitumor activity and bystander effect of adenovirally delivered tissue inhibitor of metalloproteinases-3. Mol Ther 2002; 5: 705–715
   Google Scholar
• Lam P, Sian Lim K, Mei Wang S, Hui K M. A microarray study to characterize the molecular mechanism of TIMP3-mediated tumor rejection. Mol Ther 2005; 12: 144–152
   PubMedGoogle Scholar
• Brand K, Baker A H, Perez-Canto A, Possling A, Sacharjat M, Geheeb M, Arnold W. Treatment of colorectal liver metastases by adenoviral transfer of tissue inhibitor of metalloproteinases-2 into the liver tissue. Cancer Res 2000; 60: 5723–5730
   PubMed Web of Science ®Google Scholar
• Lombard M A, Wallace T L, Kubicek M F, Petzold G L, Mitchell M A, Hendges S K, Wilks J W. Synthetic matrix metalloproteinase inhibitors and tissue inhibitor of metalloproteinase (TIMP)-2, but not TIMP1, inhibit shedding of tumor necrosis factor-alpha receptors in a human colon adenocarcinoma (Colo 205) cell line. Cancer Res 1998; 58: 4001–4007
   PubMed Web of Science ®Google Scholar
• Mitsiades N, Poulaki V, Kotoula V, Leone A, Tsokos M. Fas ligand is present in tumors of the Ewing's sarcoma family and is cleaved into a soluble form by a metalloproteinase. Am J Pathol 1998; 153: 1947–1956
   PubMedGoogle Scholar
• Guo W, Giancotti F G. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 2004; 5: 816–826
   PubMed Web of Science ®Google Scholar
• Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27–31
   PubMed Web of Science ®Google Scholar
• Pepper M S, Montesano R, Mandriota S J, Orci L, Vassalli J D. Angiogenesis: a paradigm for balanced extracellular proteolysis during cell migration and morphogenesis. Enzyme Protein 1996; 49: 138–162
   PubMedGoogle Scholar
• Ikenaka Y, Yoshiji H, Kuriyama S, Yoshii J, Noguchi R, Tsujinoue H, Yanase K, Namisaki T, Imazu H, Masaki T, Fukui H. Tissue inhibitor of metalloproteinases-1 (TIMP1) inhibits tumor growth and angiogenesis in the TIMP1 transgenic mouse model. Int J Cancer 2003; 105: 340–346
   PubMed Web of Science ®Google Scholar
• Zacchigna S, Zentilin L, Morini M, Dell'Eva R, Noonan D M, Albini A, Giacca M. AAV-mediated gene transfer of tissue inhibitor of metalloproteinases-1 inhibits vascular tumor growth and angiogenesis in vivo. Cancer Gene Ther 2004; 11: 73–80
   PubMed Web of Science ®Google Scholar
• Johnson M D, Kim H R, Chesler L, Tsao-Wu G, Bouck N, Polverini P J. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase. J Cell Physiol 1994; 160: 194–202
   PubMed Web of Science ®Google Scholar
• Fernandez H A, Kallenbach K, Seghezzi G, Grossi E, Colvin S, Schneider R, Mignatti P, Galloway A. Inhibition of endothelial cell migration by gene transfer of tissue inhibitor of metalloproteinases-1. J Surg Res 1999; 82: 156–162
   PubMed Web of Science ®Google Scholar
• Reed M J, Koike T, Sadoun E, Sage E H, Puolakkainen P. Inhibition of TIMP1 enhances angiogenesis in vivo and cell migration in vitro. Microvasc Res 2003; 65: 9–17
   PubMed Web of Science ®Google Scholar
• Yoshiji H, Harris S R, Raso E, Gomez D E, Lindsay C K, Shibuya M, Sinha C C, Thorgeirsson U P. Mammary carcinoma cells over-expressing tissue inhibitor of metalloproteinases-1 show enhanced vascular endothelial growth factor expression. Int J Cancer 1998; 75: 81–87
   PubMed Web of Science ®Google Scholar
• Martin D C, Sanchez-Sweatman O H, Ho A T, Inderdeo D S, Tsao M S, Khokha R. Transgenic TIMP1 inhibits simian virus 40 T antigen-induced hepatocarcinogenesis by impairment of hepatocellular proliferation and tumor angiogenesis. Lab Invest 1999; 79: 225–234
   PubMed Web of Science ®Google Scholar
• Akahane T, Akahane M, Shah A, Connor C M, Thorgeirsson U P. TIMP1 inhibits microvascular endothelial cell migration by MMP-dependent and MMP-independent mechanisms. Exp Cell Res 2004; 301: 158–167
   PubMed Web of Science ®Google Scholar
• Oh J, Seo D W, Diaz T, Wei B, Ward Y, Ray J M, Morioka Y, Shi S, Kitayama H, Takahashi C, Noda M, Stetler-Stevenson W G. Tissue inhibitors of metalloproteinase 2 inhibits endothelial cell migration through increased expression of RECK. Cancer Res 2004; 64: 9062–9069
   PubMed Web of Science ®Google Scholar
• Plaisier M, Kapiteijn K, Koolwijk P, Fijten C, Hanemaaijer R, Grimbergen J M, Mulder-Stapel A, Quax P H, Helmerhorst F M, van Hinsbergh V W. Involvement of membrane-type matrix metalloproteinases (MT-MMPs) in capillary tube formation by human endometrial microvascular endothelial cells: role of MT3-MMP. J Clin Endocrinol Metab 2004; 89: 5828–5836
   PubMed Web of Science ®Google Scholar
• Anand-Apte B, Pepper M S, Voest E, Montesano R, Olsen B, Murphy G, Apte S S, Zetter B. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3. Invest Ophthalmol Vis Sci 1997; 38: 817–823
   PubMed Web of Science ®Google Scholar
• Hiraoka N, Allen E, Apel I J, Gyetko M R, Weiss S J. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell 1998; 95: 365–377
   PubMed Web of Science ®Google Scholar
• Hajitou A, Sounni N E, Devy L. Down-regulation of vascular endothelial growth factor by tissue inhibitor of metalloproteinase-2: effect on in vivo mammary tumor growth and angiogenesis. Cancer Res 2001; 61: 3450–3457
   PubMed Web of Science ®Google Scholar
• Li H, Lindenmeyer F, Grenet C, Opolon P, Menashi S, Soria C, Yeh P, Perricaudet M, Lu H. AdTIMP2 inhibits tumor growth, angiogenesis, and metastasis, and prolongs survival in mice. Hum Gene Ther 2001; 12: 515–526
   PubMed Web of Science ®Google Scholar
• Lafleur M A, Handsley M M, Knauper V, Murphy G, Edwards D R. Endothelial tubulogenesis within fibrin gels specifically requires the activity of membrane-type-matrix metalloproteinases (MT-MMPs). J Cell Sci 2002; 115: 3427–3438
   PubMed Web of Science ®Google Scholar
• Bayless K J, Davis G E. Sphingosine-1-phosphate markedly induces matrix metalloproteinase and integrin-dependent human endothelial cell invasion and lumen formation in three-dimensional collagen and fibrin matrices. Biochem Biophys Res Commun 2003; 312: 903–913
   PubMedGoogle Scholar
• Feldman A L, Stetler-Stevenson W G, Costouros N G, Knezevic V, Baibakov G, Alexander H R, Jr., Lorang D, Hewitt S M, Seo D W, Miller M S, O'Connor S, Libutti S K. Modulation of tumor-host interactions, angiogenesis, and tumor growth by tissue inhibitor of metalloproteinase 2 via a novel mechanism. Cancer Res 2004; 64: 4481–4486
   Google Scholar
• Sounni N E, Roghi C, Chabottaux V, Janssen M, Munaut C, Maquoi E, Galvez B G, Gilles C, Frankenne F, Murphy G, et al. Up-regulation of vascular endothelial growth factor-A by active membrane-type 1 matrix metalloproteinase through activation of Src-tyrosine kinases. J Biol Chem 2004; 279: 13564–13574
   PubMed Web of Science ®Google Scholar
• Blavier L, Lazaryev A, Dorey F, Shackleford G M, DeClerck Y A. Matrix metalloproteinases play an active role in Wnt1-induced mammary tumorigenesis. Cancer Res 2006; 66: 2691–2699
   PubMed Web of Science ®Google Scholar
• Saunders W B, Bohnsack B L, Faske J B, Anthis N J, Bayless K J, Hirschi K K, Davis G E. Coregulation of vascular tube stabilization by endothelial cell TIMP2 and pericyte TIMP3. J Cell Biol 2006; 175: 179–191
   PubMed Web of Science ®Google Scholar
• Collen A, Hanemaaijer R, Lupu F, Quax P H, van Lent N, Grimbergen J, Peters E, Koolwijk P, van Hinsbergh V W. Membrane-type matrix metalloproteinase-mediated angiogenesis in a fibrin-collagen matrix. Blood 2003; 101: 1810–1817
   Google Scholar
• Ma D H, Chen J I, Zhang F, Hwang D G, Chen J K. Inhibition of fibroblast-induced angiogenic phenotype of cultured endothelial cells by the overexpression of tissue inhibitor of metalloproteinase (TIMP)-3. J Biomed Sci 2003; 10: 526–534
   Google Scholar
• Cruz-Munoz W, Kim I, Khokha R. TIMP3 deficiency in the host, but not in the tumor, enhances tumor growth and angiogenesis. Oncogene 2006; 25: 650–655
   PubMed Web of Science ®Google Scholar
• Fernandez C A, Moses M A. Modulation of angiogenesis by tissue inhibitor of metalloproteinase-4. Biochem Biophys Res Commun 2006; 345: 523–529
   PubMedGoogle Scholar
• Chun T H, Sabeh F, Ota I, Murphy H, McDonagh K T, Holmbeck K, Birkedal-Hansen H, Allen E D, Weiss S J. MT1-MMP-dependent neovessel formation within the confines of the three-dimensional extracellular matrix. J Cell Biol 2004; 167: 757–767
   PubMed Web of Science ®Google Scholar
• Spurbeck W W, Ng C Y, Vanin E F, Davidoff A M. Retroviral vector-producer cell-mediated in vivo gene transfer of TIMP3 restricts angiogenesis and neuroblastoma growth in mice. Cancer Gene Ther 2003; 10: 161–167
   PubMed Web of Science ®Google Scholar
• Qi J H, Ebrahem Q, Yeow K, Edwards D R, Fox P L, Anand-Apte B. Expression of Sorsby's fundus dystrophy mutations in human retinal pigment epithelial cells reduces matrix metalloproteinase inhibition and may promote angiogenesis. J Biol Chem 2002; 277: 13394–13400
   Google Scholar
• Bigg H F, Morrison C J, Butler G S, Bogoyevitch M A, Wang Z, Soloway P D, Overall C M. Tissue inhibitor of metalloproteinases-4 inhibits but does not support the activation of gelatinase A via efficient inhibition of membrane type 1-matrix metalloproteinase. Cancer Res 2001; 61: 3610–3618
   PubMed Web of Science ®Google Scholar
• Groft L L, Muzik H, Rewcastle N B, Johnston R N, Knauper V, Lafleur M A, Forsyth P A, Edwards D R. Differential expression and localization of TIMP1 and TIMP4 in human gliomas. Br J Cancer 2001; 85: 55–63
   PubMed Web of Science ®Google Scholar
• Yamada E, Tobe T, Yamada H, Okamoto N, Zack D J, Werb Z, Soloway P D, Campochiaro P A. TIMP1 promotes VEGF-induced neovascularization in the retina. Histol Histopathol 2001; 16: 87–97
   PubMed Web of Science ®Google Scholar
• Kurschat P, Zigrino P, Nischt R, Breitkopf K, Steurer P, Klein C E, Krieg T, Mauch C. Tissue inhibitor of matrix metalloproteinase-2 regulates matrix metalloproteinase-2 activation by modulation of membrane-type 1 matrix metalloproteinase activity in high and low invasive melanoma cell lines. J Biol Chem 1999; 274: 21056–21062
   PubMed Web of Science ®Google Scholar
• Kleiner D E, Stetler-Stevenson W G. Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 1999; 43(Suppl)S42–S51
   PubMed Web of Science ®Google Scholar
• Ho A T, Voura E B, Soloway P D, Watson K L, Khokha R. MMP inhibitors augment fibroblast adhesion through stabilization of focal adhesion contacts and up-regulation of cadherin function. J Biol Chem 2001; 276: 40215–40224
   PubMed Web of Science ®Google Scholar
• Reid H M, McElligott A M, McGlynn H. Phenotypic alterations in Caki-1 cells as a consequence of TIMP1 overexpression. Cancer Lett 2001; 169: 189–198
   PubMedGoogle Scholar
• Roeb E, Winograd R, Breuer B, Nguyen H, Matern S. Increased TIMP1 activity results in increased expression of gelatinases and altered cell motility. J Cell Biochem 1999; 75: 346–355
   PubMedGoogle Scholar
• Ray J M, Stetler-Stevenson W G. Gelatinase A activity directly modulates melanoma cell adhesion and spreading. EMBO J 1995; 14: 908–917
   PubMed Web of Science ®Google Scholar
• Miyake H, Hara I, Gohji K, Yamanaka K, Hara S, Arakawa S, Nakajima M, Kamidono S. Relative expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in mouse renal cell carcinoma cells regulates their metastatic potential. Clin Cancer Res 1999; 5: 2824–2829
   PubMed Web of Science ®Google Scholar
• Kioi M, Yamamoto K, Higashi S, Koshikawa N, Fujita K, Miyazaki K. Matrilysin (MMP-7) induces homotypic adhesion of human colon cancer cells and enhances their metastatic potential in nude mouse model. Oncogene 2003; 22: 8662–8670
   PubMed Web of Science ®Google Scholar
• Rolli M, Fransvea E, Pilch J, Saven A, Felding-Habermann B. Activated integrin alphavbeta3 cooperates with metalloproteinase MMP-9 in regulating migration of metastatic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 9482–9487
   PubMed Web of Science ®Google Scholar
• Lluri G, Langlois G D, Soloway P D, Jaworski D M. Tissue inhibitor of metalloproteinase-2 (TIMP2) regulates myogenesis and beta1 integrin expression in vitro. Exp Cell Res 2008; 314: 11–24
   PubMed Web of Science ®Google Scholar
• Chang H, Lee J, Poo H, Noda M, Diaz T, Wei B, Stetler-Stevenson W G, Oh J. TIMP2 promotes cell spreading and adhesion via upregulation of Rap1 signaling. Biochem Biophys Res Commun 2006; 345: 1201–1206
   Google Scholar
• Gruss C, Herlyn M. Role of cadherins and matrixins in melanoma. Curr Opin Oncol 2001; 13: 117–123
   PubMed Web of Science ®Google Scholar
• Covington M D, Burghardt R C, Parrish A R. Ischemia-induced cleavage of cadherins in NRK cells requires MT1-MMP (MMP-14). Am J Physiol Renal Physiol 2006; 290: F43–51
   PubMed Web of Science ®Google Scholar
• Covington M D, Bayless K J, Burghardt R C, Davis G E, Parrish A R. Ischemia-induced cleavage of cadherins in NRK cells: evidence for a role of metalloproteinases. Am J Physiol Renal Physiol 2005; 289: F280–288
   PubMed Web of Science ®Google Scholar
• Nash G F, Turner L F, Scully M F, Kakkar A K. Platelets and cancer. Lancet Oncol 2002; 3: 425–430
   PubMed Web of Science ®Google Scholar
• Sawicki G, Salas E, Murat J, Miszta-Lane H, Radomski M W. Release of gelatinase A during platelet activation mediates aggregation. Nature 1997; 386: 616–619
   PubMed Web of Science ®Google Scholar
• Alonso-Escolano D, Strongin A Y, Chung A W, Deryugina E I, Radomski M W. Membrane type-1 matrix metalloproteinase stimulates tumour cell-induced platelet aggregation: role of receptor glycoproteins. Br J Pharmacol 2004; 141: 241–252
   Google Scholar
• Kazes I, Elalamy I, Sraer J D, Hatmi M, Nguyen G. Platelet release of trimolecular complex components MT1-MMP/TIMP2/MMP2: involvement in MMP2 activation and platelet aggregation. Blood 2000; 96: 3064–3069
   PubMed Web of Science ®Google Scholar
• Radomski A, Jurasz P, Sanders E J, Overall C M, Bigg H F, Edwards D R, Radomski M W. Identification, regulation and role of tissue inhibitor of metalloproteinases-4 (TIMP4) in human platelets. Br J Pharmacol 2002; 137: 1330–1338
   Web of Science ®Google Scholar
• Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 2000; 14: 163–176
   PubMed Web of Science ®Google Scholar
• Fiore E, Fusco C, Romero P, Stamenkovic I. Matrix metalloproteinase 9 (MMP-9/gelatinase B) proteolytically cleaves ICAM-1 and participates in tumor cell resistance to natural killer cell-mediated cytotoxicity. Oncogene 2002; 21: 5213–5223
   PubMed Web of Science ®Google Scholar
• McQuibban G A, Gong J H, Tam E M, McCulloch C A, Clark-Lewis I, Overall C M. Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science 2000; 289: 1202–1206
   PubMed Web of Science ®Google Scholar
• Sheu B C, Hsu S M, Ho H N, Lien H C, Huang S C, Lin R H. A novel role of metalloproteinase in cancer-mediated immunosuppression. Cancer Res 2001; 61: 237–242
   PubMed Web of Science ®Google Scholar
• Mohammed F F, Smookler D S, Taylor S E, Fingleton B, Kassiri Z, Sanchez O H, English J L, Matrisian L M, Au B, Yeh W C, Khokha R. Abnormal TNF activity in Timp3-/-mice leads to chronic hepatic inflammation and failure of liver regeneration. Nat Genet 2004; 36: 969–977
   PubMed Web of Science ®Google Scholar
• Alexander C M, Werb Z. Targeted disruption of the tissue inhibitor of metalloproteinases gene increases the invasive behavior of primitive mesenchymal cells derived from embryonic stem cells in vitro. J Cell Biol 1992; 118: 727–739
   PubMed Web of Science ®Google Scholar
• Soloway P D, Alexander C M, Werb Z, Jaenisch R. Targeted mutagenesis of Timp1 reveals that lung tumor invasion is influenced by Timp1 genotype of the tumor but not by that of the host. Oncogene 1996; 13: 2307–2314
   PubMedGoogle Scholar
• Tsuchiya Y, Sato H, Endo Y, Okada Y, Mai M, Sasaki T, Seiki M. Tissue inhibitor of metalloproteinase 1 is a negative regulator of the metastatic ability of a human gastric cancer cell line, KKLS, in the chick embryo. Cancer Res 1993; 53: 1397–1402
   Google Scholar
• Koop S, Khokha R, Schmidt E E, MacDonald I C, Morris V L, Chambers A F, Groom A C. Overexpression of metalloproteinase inhibitor in B16F10 cells does not affect extravasation but reduces tumor growth. Cancer Res 1994; 54: 4791–4797
   PubMed Web of Science ®Google Scholar
• Kruger A, Fata J E, Khokha R. Altered tumor growth and metastasis of a T-cell lymphoma in Timp1 transgenic mice. Blood 1997; 90: 1993–2000
   PubMed Web of Science ®Google Scholar
• Kruger A, Sanchez-Sweatman O H, Martin D C, Fata J E, Ho A T, Orr F W, Ruther U, Khokha R. Host TIMP1 overexpression confers resistance to experimental brain metastasis of a fibrosarcoma cell line. Oncogene 1998; 16: 2419–2423
   PubMed Web of Science ®Google Scholar
• Yamauchi K, Ogata Y, Nagase H, Shirouzu K. Inhibition of liver metastasis from orthotopically implanted colon cancer in nude mice by transfection of the TIMP1 gene into KM12SM cells. Surg Today 2001; 31: 791–798
   Google Scholar
• de Lorenzo M S, Ripoll G V, Yoshiji H, Yamazaki M, Thorgeirsson U P, Alonso D F, Gomez D E. Altered tumor angiogenesis and metastasis of B16 melanoma in transgenic mice overexpressing tissue inhibitor of metalloproteinases-1. In Vivo 2003; 17: 45–50
   PubMedGoogle Scholar
• Elezkurtaj S, Kopitz C, Baker A H, Perez-Canto A, Arlt M J, Khokha R, Gansbacher B, Anton M, Brand K, Kruger A. Adenovirus-mediated overexpression of tissue inhibitor of metalloproteinases-1 in the liver: efficient protection against T-cell lymphoma and colon carcinoma metastasis. J Gene Med 2004; 6: 1228–1237
   Google Scholar
• DeClerck Y A, Perez N, Shimada H, Boone T C, Langley K E, Taylor S M. Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res 1992; 52: 701–708
   PubMed Web of Science ®Google Scholar
• Imren S, Kohn D B, Shimada H, Blavier L, DeClerck Y A. Overexpression of tissue inhibitor of metalloproteinases-2 retroviral-mediated gene transfer in vivo inhibits tumor growth and invasion. Cancer Res 1996; 56: 2891–2895
   PubMed Web of Science ®Google Scholar
• Sacco M G, Cato E M, Ceruti R, Soldati S, Indraccolo S, Caniatti M, Scanziani E, Vezzoni P. Systemic gene therapy with anti-angiogenic factors inhibits spontaneous breast tumor growth and metastasis in MMTVneu transgenic mice. Gene Ther 2001; 8: 67–70
   PubMed Web of Science ®Google Scholar
• Lee Y K, So I S, Lee S C, Lee J H, Lee C W, Kim W M, Park M K, Lee S T, Park D Y, Shin D Y, et al. Suppression of distant pulmonary metastasis of MDA-MB 435 human breast carcinoma established in mammary fat pads of nude mice by retroviral-mediated TIMP2 gene transfer. J Gene Med 2005; 7: 145–157
   Google Scholar
• Khokha R, Zimmer M J, Graham C H, Lala P K, Waterhouse P. Suppression of invasion by inducible expression of tissue inhibitor of metalloproteinase-1 (TIMP1) in B16-F10 melanoma cells. J Natl Cancer Inst 1992; 84: 1017–1022
   PubMedGoogle Scholar
• Engers R, Springer E, Michiels F, Collard J G, Gabbert H E. Rac affects invasion of human renal cell carcinomas by up-regulating tissue inhibitor of metalloproteinases (TIMP)-1 and TIMP2 expression. J Biol Chem 2001; 276: 41889–41897
   Google Scholar
• Rigg A S, Lemoine N R. Adenoviral delivery of TIMP1 or TIMP2 can modify the invasive behavior of pancreatic cancer and can have a significant antitumor effect in vivo. Cancer Gene Ther 2001; 8: 869–878
   PubMed Web of Science ®Google Scholar
• Kong Y, Poon R, Nadesan P, Di Muccio T, Fodde R, Khokha R, Alman B A. Matrix metalloproteinase activity modulates tumor size, cell motility, and cell invasiveness in murine aggressive fibromatosis. Cancer Res 2004; 64: 5795–5803
   PubMed Web of Science ®Google Scholar
• Ahn S M, Jeong S J, Kim Y S, Sohn Y, Moon A. Retroviral delivery of TIMP2 inhibits H-ras-induced migration and invasion in MCF10A human breast epithelial cells. Cancer Lett 2004; 207: 49–57
   Google Scholar
• Lu K V, Jong K A, Rajasekaran A K, Cloughesy T F, Mischel P S. Upregulation of tissue inhibitor of metalloproteinases (TIMP)-2 promotes matrix metalloproteinase (MMP)-2 activation and cell invasion in a human glioblastoma cell line. Lab Invest 2004; 84: 8–20
   PubMed Web of Science ®Google Scholar
• Sun Y, Kim H, Parker M, Stetler-Stevenson W G, Colburn N H. Lack of suppression of tumor cell phenotype by overexpression of TIMP3 in mouse JB6 tumor cells identification of a transfectant with increased tumorigenicity and invasiveness. Anticancer Res 1996; 16: 1–7
   Google Scholar
• Kang J A, Kim J T, Song H S, Bae M K, Yi E Y, Kim K W, Kim Y J. Anti-angiogenic and anti-tumor invasive activities of tissue inhibitor of metalloproteinase-3 from shark, Scyliorhinus torazame. Biochim Biophys Acta 2003; 1620: 59–64
   Google Scholar
• Yonemura Y, Endo Y, Takino T, Sakamoto K, Bandou E, Kinoshita K, Fushida S, Miwa K, Sugiyama K, Sasaki T. Membrane-type 1 matrix metalloproteinase enhances lymph node metastasis of gastric cancer. Clin Exp Metastasis 2000; 18: 321–327
   Google Scholar
• Ala-Aho R, Johansson N, Baker A H, Kahari V M. Expression of collagenase-3 (MMP-13) enhances invasion of human fibrosarcoma HT-1080 cells. Int J Cancer 2002; 97: 283–289
   PubMed Web of Science ®Google Scholar
• Hasegawa S, Koshikawa N, Momiyama N, Moriyama K, Ichikawa Y, Ishikawa T, Mitsuhashi M, Shimada H, Miyazaki K. Matrilysin-specific antisense oligonucleotide inhibits liver metastasis of human colon cancer cells in a nude mouse model. Int J Cancer 1998; 76: 812–816
   PubMed Web of Science ®Google Scholar
• London C A, Sekhon H S, Arora V, Stein D A, Iversen P L, Devi G R. A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and tumorigenicity. Cancer Gene Ther 2003; 10: 823–832
   Google Scholar
• Jiang X, Dutton C M, Qi W N, Block J A, Garamszegi N, Scully S P. siRNA mediated inhibition of MMP-1 reduces invasive potential of a human chondrosarcoma cell line. J Cell Physiol 2005; 202: 723–730
   Google Scholar
• Wang P, Nie J, Pei D. The hemopexin domain of membrane-type matrix metalloproteinase-1 (MT1-MMP) Is not required for its activation of proMMP2 on cell surface but is essential for MT1-MMP-mediated invasion in three-dimensional type I collagen. J Biol Chem 2004; 279: 51148–51155
   Google Scholar
• Itoh T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H, Itohara S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 1998; 58: 1048–1051
   PubMed Web of Science ®Google Scholar
• Itoh T, Tanioka M, Matsuda H, Nishimoto H, Yoshioka T, Suzuki R, Uehira M. Experimental metastasis is suppressed in MMP-9-deficient mice. Clin Exp Metastasis 1999; 17: 177–181
   PubMed Web of Science ®Google Scholar
• Walther S E, Denhardt D T. Directed mutagenesis reveals that two histidines in tissue inhibitor of metalloproteinase-1 are each essential for the suppression of cell migration, invasion, and tumorigenicity. Cell Growth Differ 1996; 7: 1579–1588
   Google Scholar
• Hoashi T, Kadono T, Kikuchi K, Etoh T, Tamaki K. Differential growth regulation in human melanoma cell lines by TIMP1 and TIMP2. Biochem Biophys Res Commun 2001; 288: 371–379
   Google Scholar
• Brummer O, Athar S, Riethdorf L, Loning T, Herbst H. Matrix-metalloproteinases 1, 2, and 3 and their tissue inhibitors 1 and 2 in benign and malignant breast lesions: an in situ hybridization study. Virchows Arch 1999; 435: 566–573
   PubMed Web of Science ®Google Scholar
• Joo Y E, Seo K S, Kim J, Kim H S, Rew J S, Park C S, Kim S J. Role of tissue inhibitors of metalloproteinases (TIMPs) in colorectal carcinoma. J Korean Med Sci 1999; 14: 417–423
   PubMed Web of Science ®Google Scholar
• Hidalgo M, Eckhardt S G. Development of matrix metalloproteinase inhibitors in cancer therapy. J Natl Cancer Inst 2001; 93: 178–193
   PubMed Web of Science ®Google Scholar
• Bramhall S R, Rosemurgy A, Brown P D, Bowry C, Buckels J A. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. J Clin Oncol 2001; 19: 3447–3455
   PubMed Web of Science ®Google Scholar
• Bramhall S R, Hallissey M T, Whiting J, Scholefield J, Tierney G, Stuart R C, Hawkins R E, McCulloch P, Maughan T, Brown P D, et al. Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br J Cancer 2002; 86: 1864–1870
   PubMed Web of Science ®Google Scholar
• Coussens L M, Fingleton B, Matrisian L M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002; 295: 2387–2392
   PubMed Web of Science ®Google Scholar
• Pavlaki M, Zucker S. Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials. Cancer Metastasis Rev 2003; 22: 177–203
   PubMed Web of Science ®Google Scholar
• Bissett D, O'Byrne K J, von Pawel J, Gatzemeier U, Price A, Nicolson M, Mercier R, Mazabel E, Penning C, Zhang M H, et al. Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. J Clin Oncol 2005; 23: 842–849
   PubMed Web of Science ®Google Scholar
• Leighl N B, Paz-Ares L, Douillard J Y. Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18. J Clin Oncol 2005; 23: 2831–2839
   PubMed Web of Science ®Google Scholar
• Batist G, Patenaude F, Champagne P, Croteau D, Levinton C, Hariton C, Escudier B, Dupont E. Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels. Ann Oncol 2002; 13: 1259–1263
   PubMed Web of Science ®Google Scholar
• Latreille J, Batist G, Laberge F, Champagne P, Croteau D, Falardeau P, Levinton C, Hariton C, Evans W K, Dupont E. Phase I/II trial of the safety and efficacy of AE-941 (Neovastat) in the treatment of non-small-cell lung cancer. Clin Lung Cancer 2003; 4: 231–236
   PubMedGoogle Scholar